文献速递银屑病与炎症性皮肤病

银屑病微环境与治疗反应的相关性

Association of the Psoriatic Microenvironment With Treatment Response.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该研究基于12项回顾性银屑病研究的1145份皮肤样本,利用CIBERSORT算法和随机森林等方法构建银屑病微环境(PME)评分。高PME评分与更好的治疗反应相关(PASI降低75.8%),低评分则反应较差(PASI降低53.5%)。PME评分可在临床反应出现前8-12周预测疗效。

要点

  • PME评分基于33个微环境特征基因,高分提示角化细胞分化,低分提示免疫激活。
  • 治疗第4周的PME评分可提前8-12周预测依那西普、甲氨蝶呤联合阿达木单抗及托法替布的疗效。

核心结论

  • PME评分是一种可在临床反应前预测系统性银屑病治疗疗效的生物特征评分。

研究设计与样本

  • 决策分析模型,使用12项回顾性银屑病研究的不同队列共1145份皮肤样本。
  • 发现集和验证集分别来自1个和4个独立队列,包含85和421个银屑病皮损。
  • 其中157、71、89和90个皮损分别接受依那西普、托法替布、阿达木单抗和甲氨蝶呤治疗。

主要发现

  • 22种免疫细胞亚型形成可区分银屑病皮损与健康皮肤的浸润模式。
  • 33个PME特征基因定义了2种免疫表型,并可简化为数值化PME评分。
  • 治疗第4周的PME评分可提前8至12周预测依那西普、甲氨蝶呤联合阿达木单抗及托法替布的应答状态。

临床怎么用

  • PME评分可作为个性化医疗工具,在临床反应前预测系统性治疗疗效,减少无效且昂贵的治疗暴露。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The ability to predict the efficacy of systemic psoriasis therapy based on immune profiles in skin biopsies could reduce the use of inappropriate treatment and its associated costs and adverse events. It could considerably decrease drug development trial costs as well. OBJECTIVE: To develop a bioinformatic gene signature score derived from skin mRNA to predict psoriasis treatment outcomes for a variety of therapies. DESIGN, SETTING, AND PARTICIPANTS: In this decision analytical model using 1145 skin samples from different cohorts of 12 retrospective psoriasis studies, samples were analyzed using the CIBERSORT algorithm to define the immune landscape of psoriasis lesions and controls. Random forest classification and principal component analysis algorithms were used to estimate psoriatic microenvironment (PME) signature genes and construct a PME score. Overall, 85 and 421 psoriasis lesions from 1 and 4 independent cohorts were used as discovery and validation studies, respectively. Among them, 157, 71, 89, and 90 psoriasis lesions were treated with etanercept, tofacitinib, adalimumab, and methotrexate, respectively. MAIN OUTCOMES AND MEASURES: Number of weeks after treatment initiation when responders and nonresponders could be predicted. RESULTS: Overall, 22 immune cell subtypes formed infiltration patterns that differentiated psoriasis lesions from healthy skin. In psoriasis lesions, the expression of 33 PME signature genes defined 2 immune phenotypes and in aggregate could be simplified to a numerical PME score. A high PME score, characterized by keratinocyte differentiation, correlated with a better treatment response (Psoriasis Area and Severity Index [PASI] reduction, 75.8%; 95% CI, 69.4% to 82.2%; P = .03), whereas a low PME score exhibited an immune activation signature and was associated with a worse response (PASI reduction, 53.5%; 95% CI, 45.3% to 61.7%; P = .03). The PME score at week 4 after treatment initiation correlated with future responder vs nonresponder to treatment status 8 to 12 weeks earlier than PASI reduction for etanercept, methotrexate plus adalimumab, and tofacitinib. CONCLUSIONS AND RELEVANCE: The PME score is a biometric score that may predict clinical efficacy of systemic psoriasis therapy in advance of clinical responses. As an application of personalized medicine, it may reduce the exposure of patients with psoriasis to ineffective and expensive therapies.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang G, Miao Y, Kim N, et al. Association of the Psoriatic Microenvironment With Treatment Response. JAMA Dermatol. 2020. PMID: 32876657. doi:10.1001/jamadermatol.2020.2118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。